Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network-Reference-Cited by-同舟云学术

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network

Published:2023-10-01 Issue:10 Volume:33 Page:1190-1200
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Jannin Arnaud¹²^ORCID,Giudici Fabiola³⁴,de la Fouchardière Christelle⁵,Al Ghuzlan Abir⁶,Wassermann Johanna⁷,Chougnet Cecile N.⁸,Drui Delphine⁹,Godbert Yann¹⁰,Ilouz Frédéric¹¹,Bardet Stéphane¹²,Zanetta Sylvie¹³,Roudaut Nathalie¹⁴,Batisse Lignier Marie¹⁵,Groussin Lionel¹⁶,Klein Marc¹⁷,Zerdoud Slimane¹⁸,Lamartina Livia¹⁹,Baudin Eric¹⁹,Decaussin-Petrucci Myriam²⁰²¹,Leteurtre Emmanuelle²,Borson Chazot Francoise²⁰²²,Do Cao Christine¹^ORCID,Borget Isabelle³⁴,Hadoux Julien¹⁹^ORCID,Cheav T.,Delahaye A.,Hellal M.,Boudou G.,Kergoulay C.,Kidi A.,Malekzadeh Katty,

Affiliation:

1. CHU Lille, Department of Endocrinology, Diabetology, and Metabolism, Lille, France.

2. Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER—Cancer-Heterogeneity Plasticity and Resistance to Therapies, Lille, France.

3. Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

4. Oncostat, U1018, CESP, Inserm, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, France.

5. Medical Oncology Department, Centre Léon Bérard/Research Center of Lyon (CRCL), UMR INSERM 1052, Lyon, France.

6. Department of Biology and Pathology, Gustave Roussy Cancer Campus and University Paris-Saclay, Villejuif, France.

7. Medical Oncology Department and Thyroid and Endocrine Tumors Department, Pitié-Salpêtrière University Hospital, AP-HP, IUC, Sorbonne University, Paris, France.

8. Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris, Paris, France.

9. Nantes Université, CHU Nantes, Service d'Endocrinologie-Diabétologie et Nutrition, l'institut du thorax, Nantes, France.

10. Nuclear Medicine and Endocrine Oncology Department, Institute of Bergonié, Bordeaux, France.

11. Department of Endocrinology, CHU Angers, France.

12. Department of Nuclear Medicine and Thyroid Unit, Center François Baclesse, Caen, France.

13. Nuclear Medicine Department, Center Georges François Leclerc, Dijon, France.

14. Department of Endocrinology, University Hospital of Brest, Brest, France.

15. Department of Nuclear Medicine, Center of Jean Perrin, Clermont-Ferrand, France.

16. Endocrine Department, AP-HP, Hôpital Cochin, Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.

17. Department of Endocrinology, CHU de Nancy, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.

18. Department of Nuclear Medicine, Institute Claudius Regaud, Oncology University Institute, IUCT Oncopole, Toulouse, France.

19. Département d'imagerie, Service d'Oncologie Endocrinienne, Gustave Roussy, Villejuif, France.

20. Research on Healthcare Performance (RESHAPE), INSERM U1290, EA 3738 CICLY, Université Lyon 1, Claude Bernard, Lyon, France.

21. Service d'Anatomopathologie, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre Bénite, France.

22. Endocrinology Department, Hospice Civils de Lyon, Hospital Louis-Pradel, Bron, France.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0164

Reference37 articles.

1. Anaplastic thyroid carcinoma in Denmark 1996–2012: A national prospective study of 219 patients

2. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany

3. Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients

4. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases

5. Anaplastic Thyroid Carcinoma: An Update

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of survival nomograms for patients with anaplastic thyroid carcinoma: a SEER Program-based study;2024-08-07

2. What Is the Impact of Adding Immune Checkpoint Inhibition to Dabrafenib/Trametinib in BRAF-Mutant Anaplastic Thyroid Carcinoma?;Clinical Thyroidology®;2024-04-01

3. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF^V600E-Mutated Anaplastic Thyroid Carcinoma;Thyroid®;2024-03-01

4. Correction to: Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network by Jannin et al. Thyroid 2023;33(10):1190–1200; doi: 10.1089/thy.2023.0164;Thyroid®;2024-01-01

5. Chapter 10: Management of Anaplastic Thyroid Carcinoma;Journal of Head & Neck Physicians and Surgeons;2024-01